UK govt consults on dementia care

29 June 2008

UK Health Minister Ivan Lewis has outlined proposals to improve the quality of dementia care and provide more help for people with the condition, as he launched a consultation on the first ever National Dementia Strategy. Direct costs of dementia care to Britain's National Health Service are estimated to be in the region of L3.3 billion ($6.48 billion), with the amount spent on drugs for this in England alone put at some L60.9 million.

With the full Strategy to be launched in the fall, the governments announcement includes a number of immediate actions, as well as other proposals which will be consulted on over the coming months. These include:

- an immediate review into the prescribing and use of antipsychotic drugs to treat sufferers of dementia. This work will be completed before the publication of the complete National Dementia Strategy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight